Full-Time

Senior Director

Clinical Supplies Management

Posted on 9/24/2024

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

Compensation Overview

$215k - $268.2kAnnually

+ Bonus + Equity Awards

Senior, Expert

San Diego, CA, USA

The role requires working in the office three days per week.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Supply Chain Management
Requirements
  • A minimum of a BS/BA in Chemistry, Supply Chain Management, or related field
  • Master’s degree is preferred
  • A minimum of 12 years of clinical supply management experience demonstrating a dynamically increasing scope of responsibility
  • A minimum of 5 years in a clinical supply leadership role with US and international clinical trial experience is required
  • Must be an expert in GXP requirements and is knowledgeable of industry services providers, trends, and challenges
  • A strong understanding of regulatory requirements impacting the clinical supply chain is required
  • Strong understanding of GMP working environments and regulatory guidance and regulations (e.g., ICH guidance, 21 CFR Part 211, 21 CFR Part 11)
  • Working knowledge of United States Pharmacopeia (USP), European Pharmacopeia (EP), Japanese Pharmacopeia (JP), British (BP) and other established pharmacopoeias
  • Strong understanding of EU and EC CTR regulations
  • Demonstrated problem solving abilities
  • Strong organizational and documentation skills
  • Demonstrated verbal and written communication skills
  • Ability to lead and manage change in a dynamic environment
  • Expert understanding of clinical supply chain functional interdependencies
  • Skilled at negotiating with business partners, stakeholders, service providers
  • Proficient in the ability to influence and inform senior level leaders regarding matters of significance to the department
  • Adept at creating and communicating a clear vision among team members effectively aligning resources to achieve functional area goals
  • Ability to travel up to 30% of the time both domestically and internationally
Responsibilities
  • Establishes vision and strategic direction for CTM function
  • Develops clinical supply chain resource plan to position the CTM group for future scalability
  • Ensures operational efficiency and compliance of supply chain processes compliance for packaging, labeling, sourcing, and distribution logistics
  • Identifies existing process/capabilities gaps; Prioritizes and sponsors strategic supply chain initiatives to address gaps
  • Establishes department standards and collaborates with cross functional partners to agree on expectations
  • Defines department digital supply chain system needs
  • Provides Leadership to Clinical Trial Material Team
  • Ensures CTM team effectively plans and implements in accordance with Study Team timelines
  • Defines expectations of CTM team and holds team accountable
  • Creates career development plans for CTM team members
  • Mentors CTM team
  • Leads CTM supply team meetings
  • Align operational execution practices across team members
  • Accountable for department budget
  • Defines forward-looking functional team budget and tracks spending against the budget plan
  • Identifies opportunities for cost savings and develops plans for implementation
  • Partners with Finance and Procurement to ensure financial transparency
  • Establishes relationships and collaborates with cross functional leadership including but not limited to Clinical Operations and GMP Quality to align on business timelines and priorities
  • Implements strong Vendor Management oversight model for Clinical Supply Chain Vendors
  • Leads Business Review Meetings
  • Identifies opportunities with vendors and negotiates cost saving incentives
  • Leads escalation of issues to vendor Sr. Management
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these conditions while also promoting diversity and inclusion within their operations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's DAYBUE is now available for treating Rett syndrome in the U.S.
  • The partnership with Neuren Pharmaceuticals strengthens Acadia's position in the rare disease market.
  • Increased focus on personalized medicine benefits Acadia's tailored CNS disorder therapies.

What critics are saying

  • A class action lawsuit could lead to financial liabilities and reputational damage.
  • Increased competition in CNS treatments may impact Acadia's market share.
  • Reliance on partnerships poses risks if collaborations face challenges or fail.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on CNS disorders with a strong pipeline of small molecule drugs.
  • The company has a unique partnership with Stoke Therapeutics for RNA-based therapies.
  • Acadia's documentary series raises awareness for Rett syndrome, enhancing its community engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

2%
Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Yahoo Finance
Aug 15th, 2024
Ryan Reynolds Announces More To Parkinson'S(R) Campaign

Ryan & Tammy Reynolds (Photo: Business Wire)Acadia Parkinson's Fact Sheet-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their familySAN DIEGO, August 14, 2024--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson’s disease – Parkinson’s-related hallucinations and delusions.Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to 90% of people currently do not proactively tell their physicians about these symptoms.1-3 By sharing their experiences caring for Ryan’s father, James "Jim" Reynolds, who passed away nearly a decade ago, Ryan and his mother Tammy, aim to raise awareness, educate and drive conversation between people with Parkinson’s disease, their families and their doctors about how best to talk about and treat these non-motor symptoms."My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease," Reynolds explains. "Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease."This press release features multimedia

INACTIVE